Incyte Corp (MEX:INCY)
MXN 1486 0 (0%) Market Cap: 299.60 Bil Enterprise Value: 264.63 Bil PE Ratio: 541.07 PB Ratio: 4.61 GF Score: 80/100

Incyte Corp to Discuss Opzelura (ruxolitinib) Cream FDA Approval Call Transcript

Sep 22, 2021 / 12:00PM GMT
Release Date Price: MXN1560
Operator

Hello, and welcome to the Incyte Opzelura Approval Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Christine Chiou. Please go ahead.

Christine Chiou
Incyte Corporation - Head of IR

Thank you, Kevin. Good morning, and welcome to Incyte's Conference Call and Webcast to discuss the FDA approval of Opzelura, which was announced yesterday. I have the pleasure of introducing Dr. Larry Eichenfield from the University of San Diego. He is Professor of Dermatology and Pediatrics, Vice Chair of the Department of Dermatology and Chief of Pediatric and Adolescent Dermatology at UC San Diego School of Medicine and Rady Children's Hospital, San Diego. He has also served as an investigator on some of our studies.

Speaking on the call today from Incyte are Herve; Jim Lee, our Head of Development and Inflammation and Autoimmunity; and Todd Edwards, our Dermatology Business Unit Head. Barry and Christiana will also participate in the Q&A session.

Before we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot